We narrowed to 61,682 results for: SAP

#121539-AAVrg

Ready-to-use AAV Retrograde particles produced from pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) (#121539). In addition to the viral particles, you will also receive purified pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) plasmid DNA. Synapsin-driven, HA-tagged hM3D(Gq) for neuronal activation. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

Aug. 7, 2025

Academic Institutions and Nonprofits only

#174112-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1a-mitoGFP-DIO (#174112). In addition to the viral particles, you will also receive purified pAAV-EF1a-mitoGFP-DIO plasmid DNA. EF1a-driven, Cre-dependent expression of mitochondria-targeted GFP. These AAV preparations are suitable purity for injection into animals.

Maarten Kole

Kole et al Nat Commun. 2022 Dec 9;13(1):7598. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#121539-AAV2

Ready-to-use AAV2 particles produced from pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) (#121539). In addition to the viral particles, you will also receive purified pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) plasmid DNA. Synapsin-driven, HA-tagged hM3D(Gq) for neuronal activation. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

April 3, 2023

Academic Institutions and Nonprofits only

#121538-AAV2

Ready-to-use AAV2 particles produced from pOTTC1484 - pAAV SYN1 HA-hM4D(Gi) (#121538). In addition to the viral particles, you will also receive purified pOTTC1484 - pAAV SYN1 HA-hM4D(Gi) plasmid DNA. Synapsin-driven, HA-tagged hM4D(Gi) for neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

Sept. 25, 2019

Academic Institutions and Nonprofits only

#26969-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#26966-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#26969-AAV5

Ready-to-use AAV5 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

March 7, 2018

Academic Institutions and Nonprofits only

#26966-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

April 6, 2018

Academic Institutions and Nonprofits only

#26969-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

May 9, 2018

Academic Institutions and Nonprofits only

#26969-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

March 7, 2018

Academic Institutions and Nonprofits only

#111568-AAV5

Ready-to-use AAV5 particles produced from pZac2.1-GfaABC1D-mCherry-hPMCA2w/b (#111568). In addition to the viral particles, you will also receive purified pZac2.1-GfaABC1D-mCherry-hPMCA2w/b plasmid DNA. GfaABCD1-driven, expression of mCherry fused plasma membrane calcium pump hPMCA2w/b. These AAV preparations are suitable purity for injection into animals.

Baljit Khakh

Yu et al Neuron. 2018 Aug 27. pii: S0896-6273(18)

Feb. 14, 2022

Academic Institutions and Nonprofits only

#232353-AAV8

Ready-to-use AAV8 particles produced from pAAV-DIO-BACE-HA (#232353). In addition to the viral particles, you will also receive purified pAAV-DIO-BACE-HA plasmid DNA. Syn-driven, Beta-Secretase expression. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Rivera et al Nat Methods. 2025 May;22(5):1101-1111. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#26966-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#44361-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-DIO-hM3D(Gq)-mCherry (#44361). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-hM3D(Gq)-mCherry plasmid DNA. Syn-driven, Cre-dependent, hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Krashes et al J Clin Invest. 2011 Apr;121(4):1424-8. d

Sept. 28, 2016

Academic Institutions and Nonprofits only

#44361-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-DIO-hM3D(Gq)-mCherry (#44361). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-hM3D(Gq)-mCherry plasmid DNA. Syn-driven, Cre-dependent, hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Krashes et al J Clin Invest. 2011 Apr;121(4):1424-8. d

Sept. 20, 2018

Academic Institutions and Nonprofits only

#44362-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn-DIO-hM4D(Gi)-mCherry (#44362). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-hM4D(Gi)-mCherry plasmid DNA. Syn-driven, Cre-dependent hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Krashes et al J Clin Invest. 2011 Apr;121(4):1424-8. d

Dec. 1, 2016

Academic Institutions and Nonprofits only

#44361-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn-DIO-hM3D(Gq)-mCherry (#44361). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-hM3D(Gq)-mCherry plasmid DNA. Syn-driven, Cre-dependent, hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Krashes et al J Clin Invest. 2011 Apr;121(4):1424-8. d

Dec. 1, 2016

Academic Institutions and Nonprofits only

#140554-AAV9

Ready-to-use AAV9 particles produced from pAAV-hsyn-GRAB_DA2h (#140554). In addition to the viral particles, you will also receive purified pAAV-hsyn-GRAB_DA2h plasmid DNA. Synapsin-driven expression of high-affinity GRAB_DA2h dopamine sensor in neurons. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Sun et al Nat Methods. 2020 Nov;17(11):1156-1166.

Aug. 9, 2021

Academic Institutions and Nonprofits only

#44362-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-DIO-hM4D(Gi)-mCherry (#44362). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-hM4D(Gi)-mCherry plasmid DNA. Syn-driven, Cre-dependent, hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Krashes et al J Clin Invest. 2011 Apr;121(4):1424-8. d

Sept. 28, 2016

Academic Institutions and Nonprofits only

#44362-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-DIO-hM4D(Gi)-mCherry (#44362). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-hM4D(Gi)-mCherry plasmid DNA. hSyn-driven, Cre-dependent, hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Krashes et al J Clin Invest. 2011 Apr;121(4):1424-8. d

Sept. 20, 2018

Academic Institutions and Nonprofits only